A woman in her 70s has shared her experience of discovering cancer only after proactively contacting a breast screening unit, sparking a conversation about current NHS guidelines that typically cease routine mammograms after age 70. Carol Turansky from Essex is urging other women in her age group to self-refer for mammograms if they have concerns.

Sam Robinson, a representative from the cancer charity Big C and a former breast cancer nurse, explained that routine breast screening typically stops after 70 for several reasons. These include the possibility of other existing health issues in older patients and concerns that cancer treatments might be detrimental to their overall health. She noted that research suggests it is more likely for someone in their older years to die with breast cancer rather than from it.

Sam Robinson, from the cancer charity Big C.

Despite these considerations, Robinson emphasized that screening remains important, especially if women notice changes or have any concerns. She advised that women over 70 who wish to continue with routine mammograms, which are typically offered every three years, can contact their local breast screening unit directly. Alternatively, they can consult their GP if they notice any changes. "If people aren't going for screening, something could easily be missed," she stated.

NHS England indicated that the risk of overdiagnosis, where cancers are detected that may never cause harm, increases with age. A spokesperson for the Department of Health and Social Care (DHSC) commented that decisions regarding breast cancer screening are based on the best available evidence, with the independent UK National Screening Committee continuously reviewing all programs.

A female worker in a white lab coat and blue gloves screens a lady with short grey hair.

Currently, Cancer Research UK and AgeX are supporting a UK trial focused on examining the risks and benefits of extending breast cancer screening to women aged between 47 and 49, and 71 and 73. A report detailing the findings of this trial is anticipated in 2027.